The purpose of activity is to review the safety and efficacy data from RADIATE, a randomized, placebo-controlled trial of tocilizumab in patients with RA who exhibited an inadequate response to one or more tumor necrosis factor inhibitors.

1. Outline the study design of RADIATE.
2. Compare and contrast the American College of Rheumatology responses by visit for the placebo- and tocilizumab-treated groups.
3. Describe the adverse events reported in the placebo and tocilizumab groups.

The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Cleveland Clinic Foundation Center for Continuing Education designates this educational activity for a maximum of .75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This activity may be submitted for American Osteopathic Association Continuing Medical Education credit in Category 2.

In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.

The following faculty has indicated that he may have a relationship, which in the context of his presentation(s), could be perceived as a potential conflict of interest: